Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 8:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Membranous Nephropathy Clear all

Conditions: Primary Membranous Nephropathy
Interventions: Povetacicept, Tacrolimus; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 28
States / cities: Montgomery, Alabama • Surprise, Arizona • Los Angeles, California + 24 more

Conditions: Membranous Glomerulonephritis, Lupus Membranous Nepropathy
Interventions: Sirolimus; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 13 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Kidney Failure
Interventions: Soluble Ferric Pyrophosphate, Placebo; Drug · Other
Lead sponsor: Rockwell Medical Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Primary Membranous Nephropathy
Interventions: budoprutug; Drug
Lead sponsor: Climb Bio, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Denver, Colorado • Orlando, Florida • Atlanta, Georgia + 3 more

Conditions: Renal Cell Carcinoma
Interventions: CTT1057; Drug
Lead sponsor: Cancer Targeted Technology; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Alport Syndrome, Thin Basement Membrane Disease, Hereditary Nephritis
Interventions: Longitudinal data collection; Other
Lead sponsor: Alport Syndrome Foundation; Other
Eligibility: 0 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2048
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Primary Membranous Nephropathy
Interventions: ALXN1920, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Loma Linda, California • San Diego, California • Minneapolis, Minnesota + 2 more

Conditions: Lupus Membranous Nephropathy
Interventions: Filgotinib, Lanraplenib, Filgotinib placebo, Lanraplenib placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 7
States / cities: Birmingham, Alabama • Palo Alto, California • Gainesville, Florida + 4 more

Conditions: Glomerulonephritis, Membranous, antiPLA2R Positive
Interventions: MOR202; Drug
Lead sponsor: HI-Bio, A Biogen Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 11
States / cities: Azusa, California • San Francisco, California • Torrance, California + 8 more

Conditions: Primary Membranous Nephropathy
Interventions: SNP-ACTH (1-39) Gel, Rituximab; Drug
Lead sponsor: Cerium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 19
States / cities: Los Angeles, California • San Dimas, California • Tarzana, California + 15 more

Conditions: Membranous Nephropathy, Nephrotic Syndrome
Interventions: Belimumab, Placebo for Belimumab, Rituximab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 20
States / cities: Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 17 more

Conditions: Idiopathic Membranous Nephropathy
Interventions: Rituximab, Cyclosporine; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 18
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 13 more

Conditions: Primary Membranous Nephropathy
Interventions: Surovatamig; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 7
States / cities: Los Angeles, California • Iowa City, Iowa • Bethesda, Maryland + 2 more

Conditions: Chronic Kidney Disease, Chronic Renal Disease
Interventions: Polyflux HD-C4 Big, HD-C4 Small, Optiflux 160NR, Optiflux 200NR; Device
Lead sponsor: Vantive Health LLC; Industry
Eligibility: 19 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Primary Membranous Nephropathy
Interventions: Felzartamab, Tacrolimus, Standard of Care IST; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 16
States / cities: Huntsville, Alabama • Fresno, California • Los Angeles, California + 12 more

Conditions: Kidney Diseases, Acute Injury of Kidney, Renal Failure, Renal Insufficiency, Neonatal Renal Disorder (Disorder)
Interventions: Not listed
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 0 Days to 17 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: pMN, IgAN, Nephrotic Syndrome, MCD, FSGS
Interventions: Atacicept; Drug
Lead sponsor: Vera Therapeutics, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Glomerulonephritis, Membranous
Interventions: Belimumab 10 mg, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: St Louis, Missouri • Chapel Hill, North Carolina

Conditions: Glomerular Disease
Interventions: Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks; Dietary Supplement
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 5 Years to 30 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 5
States / cities: Wilmington, Delaware • Baltimore, Maryland • New Hyde Park, New York + 1 more

Conditions: Acute Kidney Injury
Interventions: biomarker levels; Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Membranous Nephropathy
Interventions: ACTHar; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 70 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Nephrotic Syndrome, Membranous Nephropathy
Interventions: Apixaban 5 MG; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 79 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Kidney Cancer
Interventions: human prostate-specific membrane antigen plasmid DNA vaccine, mouse prostate-specific membrane antigen plasmid DNA vaccine; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Fluid Overload, Glomerulosclerosis, Focal Segmental, Edema, Membranous Nephropathy, Minimal Change Disease, Minimal Change Nephrotic Syndrome, IgM Nephropathy, Nephrotic Syndrome, Glomerular Disease, Nephrotic Syndrome, Minimal Change, Nephrotic Syndrome in Children, Nephrotic Syndrome With Edema (Diagnosis), FSGS
Interventions: Interview; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 2 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Search by objective public record fields.

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy

Quantitative Mass Transfer of SFP-iron From Dialysate to Blood in CKD-HD Patients

A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma

ASF Alport Patient Registry

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)

Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)

A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy

Belimumab With Rituximab for Primary Membranous Nephropathy

MEmbranous Nephropathy Trial Of Rituximab

A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease

Comparative Effects Of Dialysate Flow Rate And Membrane Packing On The Performance Of Dialyzers Used For Hemodialysis

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

Hemofilter Life Span, ECLS And/or CRRT

Atacicept in Multiple Glomerular Diseases

Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy

Vitamin D Supplementation in Glomerular Disease

Renal Biomarkers to Predict Recovery Following Venoarterial Extracorporeal Membrane Oxygenation

Adrenocorticotropic Hormone in Membranous Nephropathy

A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome

Vaccine Therapy in Treating Patients With Kidney Cancer

Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.